Estimating cancer risk from
Publication/Presentation Date
2-1-2020
Abstract
BACKGROUND: Increasing recognition that transthyretin cardiac amyloidosis (ATTR-CA) is much more common than previously appreciated and the emergence of novel disease-modifying therapeutic agents have led to a paradigm shift in which ATTR-CA screening is considered in high-risk populations, such as patients with heart failure with preserved ejection fraction (HFpEF) or aortic stenosis. Radiation risk from
METHODS AND RESULTS: Radiation doses to individual organs from
CONCLUSION: Very low cancer risks associated with
Volume
27
Issue
1
First Page
215
Last Page
224
ISSN
1532-6551
Published In/Presented At
Einstein, Andrew J et al. “Estimating cancer risk from 99mTc pyrophosphate imaging for transthyretin cardiac amyloidosis.” Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology vol. 27,1 (2020): 215-224. doi:10.1007/s12350-018-1307-7
Disciplines
Medicine and Health Sciences
PubMedID
29850972
Department(s)
Department of Medicine
Document Type
Article